MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today the company will present three posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress to be held January 28 through February 1, 2026, in Dublin, Ireland. The presentations highlight clinical data in pulmonary arterial hypertension (PAH) and pulmonary hypertension as ...

Sale of a legacy Mark IV-g satellite enables HEO to expand its specialised Non-Earth Imaging services while providing a dedicated on-orbit testbed that grants Australian interests priority access for remote sensing developmentSYDNEY, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Satellogic, Inc. (NASDAQ: SATL) and HEO today announced a landmark agreement that establishes a significant new pillar of Australian sovereign space capability. Through the full title acquisition of the in-orbit NewSat-34™ satellite, a legacy M ...

CHICAGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Portillo's, the iconic Chicago-based fast-casual restaurant famous for its Italian beef sandwiches, char-broiled burgers, crinkle-cut fries, cake shakes and more, is heating up Valentine’s Day with the launch of five new flavor-packed dipping sauces available at all restaurants nationwide starting today. To celebrate the launch, Portillo’s is offering members of its loyalty program, Portillo’s Perks, an exclusive opportunity to dip, dunk and discover its bolder fl ...

Core Viewpoint - Quoin Pharmaceuticals has received confirmation from the Japanese MHLW that its lead product candidate QRX003 qualifies for both Orphan Drug Designation and Fast Track regulatory review in Japan, aiming to self-commercialize the product if approved [1][3]. Group 1: Regulatory Designation - QRX003 has been granted Orphan Drug Designation by both the U.S. FDA and the European Medicines Agency in 2025, and is now seeking similar status in Japan [1][2]. - The MHLW's Orphan Drug Designation program offers benefits such as R&D subsidies, tax credits for clinical testing, reduced application fees, priority review, and ten years of market exclusivity if approved [2]. Group 2: Clinical Development - QRX003 lotion (4%) is currently being evaluated in two late-stage pivotal clinical trials for Netherton Syndrome, with enrollment expected to be completed in the first half of 2026 [3]. - Top-line data from these trials is anticipated in the second half of 2026, with a New Drug Application (NDA) submission planned for late 2026 or early 2027 [3]. Group 3: Company Strategy - The company plans to establish its own commercial infrastructure in Japan, which is one of the three core territories for QRX003 and other pipeline products [3]. - Quoin Pharmaceuticals is committed to completing the clinical development of QRX003 urgently to address the needs of patients suffering from Netherton Syndrome [3].

NORTH PALM BEACH, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") today announced allocating further capital to its digital treasury management strategy with the purchase of Bitcoin, bringing its total allocation in cryptocurrency to $18 million across Bitcoin and Ethereum. The investment has been executed according to internally developed models to preserve long-term optionality across volatile market regimes and was made as part of the Company’s bro ...

Atlanta, GA, Jan. 27, 2026 (GLOBE NEWSWIRE) -- ScanTech AI Systems Inc. (the "Company" or "ScanTech AI") (Nasdaq: STAI) today announced that its Chief Executive Officer, Dolan Falconer, and Chief Financial Officer, James White, presented on behalf of the Company at a hearing before the Nasdaq Hearings Panel on January 22, 2026. During the hearing, management outlined the Company’s progress to date and its ongoing plan to address the remaining listing compliance matter, consistent with the written submission ...

VANCOUVER, Washington, Jan. 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced that a compassionate benefactor has formally committed funding to support the Company’s Expanded Access Pro ...

Alpha selected as the first Medspa platform partner given their commitment to innovation, education, and breaking through barriersNEW YORK and SACRAMENTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced that it has partnered with Alpha Aesthetic Partners for the Aesthetics Leadership with Obagi‘s Hyaluronic Acid (ALOHA) Program. Alpha ...

Company to Centralize AI, Data, Capital Allocation, and Governance, Enabling Modular Expansion Across Its PortfolioKUALA LUMPUR, Malaysia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”) today announced a strategic transformation into an AI-native platform, repositioning the Company to enhance scalability, capital efficiency, and execution discipline across its portfolio of businesses. Under the new model, VCI Global will operate as a centralized AI-driven ...

The integration of infrastructures in trading, payment, custody, and settlement provides global customers with a seamless and near-instant payment experience through OwlPay ARLINGTON, Va. and HONG KONG, Jan. 27, 2026 (GLOBE NEWSWIRE) -- OBOOK Holdings Inc. (NASDAQ: OWLS) (“OwlTing”), a global fintech company, and Arta Global Markets Limited (“AGML”), a Hong Kong-based financial institution regulated by the Securities and Futures Commission of Hong Kong (SFC), today announced a partnership to develop joint p ...